News
Press Releases
GRAIL Announces Validation of its Multi-Cancer Early Detection Test Published in Annals of Oncology
March 30, 2020
GRAIL Initiates First Interventional Study Using its Multi-Cancer Early Detection Test to Guide Clinical Care
February 18, 2020
GRAIL Appoints Gautam Kollu as Chief Commercial Officer
December 16, 2019
GRAIL Appoints Matthew Young as Chief Operating Officer and Chief Financial Officer
October 7, 2019
GRAIL Announces Positive Validation Data for its Multi-Cancer Early Detection Test
October 7, 2019
GRAIL Appoints Marissa Song as General Counsel and Corporate Secretary
September 30, 2019
GRAIL to Present New Data in Late-Breaking Oral Presentation at the European Society for Medical Oncology (ESMO) 2019 Congress
September 27, 2019
GRAIL Appoints Rodger Currie as Head of Government Affairs and Alliance Development
August 26, 2019
GRAIL Announces Appointment of Hans Bishop as Chief Executive Officer and Strengthens Leadership Team and Board of Directors with New Appointments
June 6, 2019
GRAIL Announces Positive New Data with Multi-Cancer Early Detection Blood Test from CCGA Study
May 31, 2019
GRAIL Announces Promising New Data with Early Detection Blood Test to be Presented at 2019 American Society of Clinical Oncology Annual Meeting
May 15, 2019
GRAIL Announces Significant Progress with Multi-Cancer Early Detection Test Including FDA Breakthrough Device Designation
May 13, 2019
GRAIL Announces Appointment of Catherine Friedman as Chair of GRAIL Board
December 10, 2018
GRAIL Announces Plans to Initiate SUMMIT Study to Support Development of Blood Test for Early Cancer Detection
December 3, 2018
GRAIL to Present New Data from the Circulating Cell-free Genome Atlas (CCGA) Study at the European Society for Medical Oncology (ESMO) 2018 Congress
October 19, 2018
GRAIL Announces Appointment of Renée Galá as Chief Financial Officer
October 4, 2018
GRAIL Announces Appointment of Hal Barron and Hans Bishop to its Board of Directors
August 9, 2018
GRAIL Announces Appointment of Key Executives as Company Makes Continued Progress in Development of Early Detection Products
July 9, 2018
GRAIL Announces Data on Detection of Early-Stage Lung Cancers
June 2, 2018
GRAIL Announces $300 Million Raised in Oversubscribed Series C Financing
May 21, 2018
GRAIL to Present New Data from Circulating Cell-free Genome Atlas (CCGA) Study at 2018 American Society of Clinical Oncology Annual Meeting
May 16, 2018
GRAIL Announces Data from Prototype Blood Tests for Early Cancer Detection
April 17, 2018
GRAIL Announces Appointment of Jennifer Cook as Chief Executive Officer
December 14, 2017
GRAIL Appoints Chairman Bill Rastetter to Chief Executive Officer
August 2, 2017
GRAIL Announces Data From Early Research Analyzing its High-Intensity Sequencing Approach
June 3, 2017
GRAIL and Cirina Combine to Create Global Company Focused on Early Detection of Cancer
May 31, 2017
GRAIL Announces Board of Directors Appointments
May 4, 2017
GRAIL Initiates the STRIVE Study to Advance Development of Blood Tests to Detect Cancer Early
April 20, 2017
GRAIL Closes Over $900 Million Initial Investment in Series B Financing to Develop Blood Tests to Detect Cancer Early
March 1, 2017
GRAIL Plans to Raise in Excess of $1B in Series B Funding
January 5, 2017
GRAIL Announces Circulating Cell-free Genome Atlas (CCGA) Study as Foundation for Development of Blood Test to Detect Cancer Early
December 1, 2016
GRAIL Hires Google Executive Jeff Huber as CEO to Lead Development for Early Cancer Detection
February 10, 2016
Illumina Forms New Company to Enable Early Cancer Detection via Blood-Based Screening
January 10, 2016